The opinion of the Transparency Committee concerning the reimbursement of Evrysdi® (or risdiplam) has just been published.
In SMA type I, II and III, Evrysdi® obtains a favorable opinion for reimbursement in patients over 2 years of age, with a significant AB and ASMR:
- III (or moderate) for patients with non-ambulatory SMA type II and III,
- V (or absence) for ambulatory SMA type III patients.
In type IV SMA or in pre-symptomatic patients, the opinion is unfavorable for reimbursement, with an insufficient AB (in the absence of data, to date, for pre-symptomatic patients).
The treatment decision must be taken on a case-by-case basis during multidisciplinary consultation meetings (RCP) organized at the national level by the FILNEMUS rare neuromuscular disease sector.
EVRYSDI – Opinion on Medicines – Posted on September 30, 2021, Haute Autorité de Santé [Online] [consulted on October 12, 2021]
EVRYSDI – Opinion on Medicines – Posted on September 30, 2021, Haute Autorité de Santé [Online] [consulted on October 12, 2021]
